What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Alan F. List mainly focuses on Internal medicine, Myelodysplastic syndromes, Leukemia, Immunology and Cancer research.
His Internal medicine research includes elements of Gastroenterology, Azacitidine, Surgery and Oncology.
In his study, Thalidomide and Phases of clinical research is strongly linked to Lenalidomide, which falls under the umbrella field of Myelodysplastic syndromes.
His Leukemia study combines topics from a wide range of disciplines, such as Myeloid, Acute promyelocytic leukemia, Myeloid leukemia, Chronic myelomonocytic leukemia and Pharmacology.
His study focuses on the intersection of Immunology and fields such as Haematopoiesis with connections in the field of CD8.
His work deals with themes such as Genetics, Somatic cell, Progenitor cell, Molecular biology and Bone marrow, which intersect with Cancer research.
His most cited work include:
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (1802 citations)
- Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (1155 citations)
- Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion (1019 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Myelodysplastic syndromes, Oncology, Immunology and Lenalidomide.
His Internal medicine study combines topics in areas such as Gastroenterology, Azacitidine and Surgery.
His biological study spans a wide range of topics, including Neutropenia and Chemotherapy.
His study looks at the relationship between Myelodysplastic syndromes and fields such as Cancer research, as well as how they intersect with chemical problems.
His work carried out in the field of Oncology brings together such families of science as Hypomethylating agent, Chronic myelomonocytic leukemia, Transplantation and Cohort.
His Lenalidomide research is multidisciplinary, incorporating elements of Clinical trial, Thalidomide, Hematology, Erythropoiesis and Adverse effect.
He most often published in these fields:
- Internal medicine (56.61%)
- Myelodysplastic syndromes (41.83%)
- Oncology (30.89%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (56.61%)
- Oncology (30.89%)
- Myelodysplastic syndromes (41.83%)
In recent papers he was focusing on the following fields of study:
Alan F. List focuses on Internal medicine, Oncology, Myelodysplastic syndromes, Cancer research and Lenalidomide.
His research in Internal medicine focuses on subjects like Azacitidine, which are connected to Decitabine.
His research in Oncology intersects with topics in Transplantation, Myeloid, Leukemia, Hypomethylating agent and Cohort.
The study incorporates disciplines such as Anemia, Disease and Gene mutation in addition to Myelodysplastic syndromes.
Alan F. List combines subjects such as Pyroptosis, Haematopoiesis, Mutation, Erythropoiesis and Downregulation and upregulation with his study of Cancer research.
His Lenalidomide research includes themes of Erythropoietin, Adverse effect and Thalidomide.
Between 2015 and 2021, his most popular works were:
- Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study (127 citations)
- Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117 (119 citations)
- The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype (116 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Alan F. List spends much of his time researching Internal medicine, Myelodysplastic syndromes, Oncology, Cancer research and Lenalidomide.
International Prognostic Scoring System, Myeloid leukemia, Clinical trial, Adverse effect and Phases of clinical research are among the areas of Internal medicine where Alan F. List concentrates his study.
His Myelodysplastic syndromes study is concerned with the field of Immunology as a whole.
His study in Oncology is interdisciplinary in nature, drawing from both Cancer, Survival rate, Case-control study, Leukemia and Transplantation.
His Cancer research research is multidisciplinary, relying on both Haematopoiesis, Mutation, Erythropoiesis, Downregulation and upregulation and Bone marrow.
His studies in Lenalidomide integrate themes in fields like Erythropoietin, Lower risk, Thalidomide and Synthetic lethality.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
